Literature DB >> 8352589

Human gene therapy.

R A Morgan1, W F Anderson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8352589     DOI： 10.1146/annurev.bi.62.070193.001203

Source DB:  PubMed          Journal:  Annu Rev Biochem        ISSN： 0066-4154            Impact factor:   23.643


× No keyword cloud information.
  44 in total

1.  Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA.

Authors:  T Kuwabara; M Warashina; T Tanabe; K Tani; S Asano; K Taira
Journal:  Nucleic Acids Res       Date:  1997-08-01       Impact factor: 16.971

Review 2.  Use of localised gene transfer to develop new treatment strategies for the salivary component of Sjögren's syndrome.

Authors:  M R Kok; B J Baum; P P Tak; S R Pillemer
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

Review 3.  Targeting site-specific chromosome integration.

Authors:  Patricia Nuno-Gonzalez; Hsu Chao; Kazuhiro Oka
Journal:  Acta Biochim Pol       Date:  2005-06-03       Impact factor: 2.149

Review 4.  High-level secretion of growth hormone by retrovirally transduced primary human keratinocytes: prospects for an animal model of cutaneous gene therapy.

Authors:  Cibele Nunes Peroni; Cláudia Regina Cecchi; Renata Damiani; Carlos R J Soares; Maria Teresa C P Ribela; Rosângela do Rocio Arkaten; Paolo Bartolini
Journal:  Mol Biotechnol       Date:  2006-10       Impact factor: 2.695

Review 5.  Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects.

Authors:  R A Stull; F C Szoka
Journal:  Pharm Res       Date:  1995-04       Impact factor: 4.200

6.  High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes.

Authors:  B A Bunnell; L M Muul; R E Donahue; R M Blaese; R A Morgan
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

7.  Recombinant, replication-defective adenovirus gene transfer vectors induce cell cycle dysregulation and inappropriate expression of cyclin proteins.

Authors:  R P Wersto; E R Rosenthal; P K Seth; N T Eissa; R E Donahue
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

8.  E- vectors: development of novel self-inactivating and self-activating retroviral vectors for safer gene therapy.

Authors:  J G Julias; D Hash; V K Pathak
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  Molecular evidence for two forms of Crohn disease.

Authors:  E C Gilberts; A J Greenstein; P Katsel; N Harpaz; R J Greenstein
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

10.  High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G.

Authors:  R K Akkina; R M Walton; M L Chen; Q X Li; V Planelles; I S Chen
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.